Pertuzumab, Trastuzumab, and an Aromatase Inhibitor for HER2-Positive and Hormone Receptor–Positive Metastatic or Locally Advanced Breast Cancer: PERTAIN Final Analysis

PURPOSE: In PERTAIN's primary analysis (31 months’ median follow-up), adding pertuzumab to trastuzumab and an aromatase inhibitor (AI) with/without chemotherapy significantly improved progression-free survival (PFS) in patients with previously untreated HER2-positive and hormone receptor–positi...

Descripción completa

Detalles Bibliográficos
Autores principales: Arpino, Grazia, de la Haba Rodríguez, Juan, Ferrero, Jean-Marc, De Placido, Sabino, Osborne, C. Kent, Klingbiel, Dirk, Revelant, Valentine, Wohlfarth, Christine, Poppe, Raf, Rimawi, Mothaffar F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2023
Materias:
Clinical Trials: Targeted Therapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10102835/
https://www.ncbi.nlm.nih.gov/pubmed/36716289
http://dx.doi.org/10.1158/1078-0432.CCR-22-1092

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10102835/
https://www.ncbi.nlm.nih.gov/pubmed/36716289
http://dx.doi.org/10.1158/1078-0432.CCR-22-1092

Ejemplares similares